| HCPCS | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Drug Class | Minor Drug Class | Oral (Y/N) | FDA Approval Year | FDA Discontinuation Year | CMS Effective Date | CMS Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| C9476 | Daratumumab | Darzalex | 10 mg | Immunotherapy | Monoclonal Antibody | CD38 | No | 2015 | Jul 1, 2016 | In Use | ||
| J9176 | Elotuzumab | Empliciti | 1 mg | Immunotherapy | Monoclonal Antibody | SLAMF7 | No | 2015 | Jan 1, 2017 | In Use | ||
| J0202 | Alemtuzumab | Lemtrada | 1 mg | Immunotherapy | Monoclonal Antibody | CD52 | No | 2001 | Jan 1, 2016 | In Use | ||
| J9076 | Cyclophosphamide (Baxter) | Cyclophosphamide (Baxter) | 5mg | Chemotherapy | Alkylating Agent | Nitrogen Mustard | No | 2024 | Dec 17, 2024 | In Use | ||
| J9600 | Porfimer | Photofrin | 75 mg | Chemotherapy | Photosensitizing Agent | Cytotoxin | No | 1995 | Jan 1, 1998 | In Use | ||
| NA | Dabrafenib | Tafinlar | 50 mg | Chemotherapy | Tyrosine Kinase Inhibitor | BRAF | Yes | 2013 | Jan 1, 2004 | In Use | ||
| J9184 | Gemcitabine (avyxa) | Avgemsi | 200mg | Chemotherapy | Antimetabolite | Pyrimidine Analog | No | 2025 | Jan 1, 2026 | In Use | ||
| C9004 | Gemtuzumab ozogamicin | Mylotarg | 5 mg | Immunotherapy | Drug Antibody Conjugate | CD33 | No | 2000 | Jan 1, 2004 | Dec 31, 2005 | No Longer Used | |
| C9069 | Belantamab mafodotin-blmf | Blenrep | 0.5mg | Immunotherapy | Drug Antibody Conjugate | BCMA | No | 2020 | Jan 1, 2021 | No Longer Used | ||
| NA | Bexarotene | Targretin | 75mg | Chemotherapy | Immunomodulator | Retinoic Acid Derivative | Yes | 2014 | In Use | |||
| J9308 | Ramucirumab | Cyramza | 5mg | Immunotherapy | Monoclonal Antibody | VEGFR | No | 2014 | Jan 1, 2016 | In Use | ||
| J9130 | Dacarbazine | Dacarbazine | 100 mg | Chemotherapy | Alkylating Agent | Purine Analog | No | 1975 | Jan 1, 1986 | In Use | ||
| C9415 | Doxorubicin | Adriamycin | 10 mg | Chemotherapy | Antitumor Antibiotic | Anthracycline | No | 1989 | Jan 1, 2004 | Dec 31, 2005 | No Longer Used | |
| J9276 | Zanidatamab-hrii | ZIIHERA | 2mg | Immunotherapy | Bispecific Antibody | HER2 | No | 2024 | Jul 9, 2025 | In Use | ||
| NA | Enasidenib mesylate | Idhifa | 100 mg | Chemotherapy | Enzyme Inhibitor | IDH2 | Yes | 2017 | In Use | |||
| NA | Panobinostat | Farydak | 10 mg | Chemotherapy | Enzyme Inhibitor | HDAC | Yes | 2015 | In Use | |||
| NA | Ruxolitinib | Jakafi | 5 mg | Chemotherapy | Enzyme Inhibitor | JAK 1/2 | Yes | 2011 | In Use | |||
| NA | Ruxolitinib | Jakafi | 15 mg | Chemotherapy | Enzyme Inhibitor | JAK 1/2 | Yes | 2011 | In Use | |||
| J7512 | Prednisone | Deltasone, PredniSONE Intensol, Rayos | 1 mg | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Yes | 1974 | Jan 1, 2016 | In Use | ||
| NA | Pomalidomide | Pomalyst | 4 mg | Immunotherapy | Immunomodulator | Thalidomide Analog | Yes | 2013 | In Use | |||
| Q5107 | Bevacizumab-awwb | Mvasi | 10mg | Immunotherapy | Monoclonal Antibody | VEGFR | No | 2018 | Jan 1, 2019 | In Use | ||
| J9177 | Enfortumab vedotin-ejfv | Padcev | 0.25mg | Immunotherapy | Drug Antibody Conjugate | Nectin-4 | No | 2019 | Jul 1, 2020 | In Use | ||
| J9314 | Pemetrexed (Teva) | Pemetrexed (Teva) | 10mg | Chemotherapy | Antimetabolite | Folic Acid Analog | No | 2022 | Dec 21, 2022 | In Use | ||
| NA | Pomalidomide | Pomalyst | 1 mg | Immunotherapy | Immunomodulator | Thalidomide Analog | Yes | 2013 | In Use | |||
| C9307 | Linvoseltamab-gcpt | Lynozyfic | 1mg | Immunotherapy | Bispecific Antibody | BCMA, CD3 | No | 2025 | Jan 1, 2026 | In Use |
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has
not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in
specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is
truly not available.
Home